Meeting
2015 ASCO Annual Meeting
A phase I study combining bendamustine with rituximab, etoposide and carboplatin (TREC) in patients with aggressive relapsed or refractory lymphoma.
Authors
L. Elizabeth Budde
City of Hope National Medical Center, Duarte, CA
L. Elizabeth Budde , Daniel B. Martin , Mary Philip , Andrei R. Shustov , Theodore Gooley , Tara L Chen , Edward N. Libby , Eric Y. Chen , Kiarash Kojouri , Alan Langerak , Jennifer E Roden , Britt E Kammerer , Nancy L Knudsen , Stephen Douglas Smith , Oliver W. Press , Ajay K. Gopal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT01165112
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8533)
DOI
10.1200/jco.2015.33.15_suppl.8533
Abstract #
8533
Poster Bd #
350
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma: A phase II clinical trial.
First Author: Tongyu Lin
Poster
2017 ASCO Annual Meeting
Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
First Author: Robert W. Chen
Poster
2015 ASCO Annual Meeting
Bendamustine and rituximab and lenalidomide (BRR) in the treatment of relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final results of phase 1 study NCCTG N1088/ALLIANCE.
First Author: Grzegorz S. Nowakowski
Poster
2012 ASCO Annual Meeting
A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
First Author: Michinori Ogura